ATOS
Income statement / Annual
Last year (2025), Atossa Therapeutics Inc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Atossa Therapeutics Inc's net income was -$34.77 M.
See Atossa Therapeutics Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$17.00 K
|
$23.00 K
|
$8.00 K
|
$23.00 K
|
$46.60 K
|
$52.79 K
|
$44.20 K
|
$128.99 K
|
$303.48 K
|
| Gross Profit |
$0.00
|
-$17.00 K
|
-$23.00 K
|
-$8.00 K
|
-$23.00 K
|
-$46.60 K
|
-$52.79 K
|
-$44.20 K
|
-$128.99 K
|
-$303.48 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$21.19 M
|
$14.12 M
|
$17.33 M
|
$15.08 M
|
$9.21 M
|
$6.61 M
|
$7.13 M
|
$4.21 M
|
$2.33 M
|
$770.43 K
|
| General & Administrative Expenses |
$15.96 M
|
$13.50 M
|
$14.04 M
|
$12.61 M
|
$11.31 M
|
$8.00 M
|
$10.62 M
|
$7.22 M
|
$4.86 M
|
$6.48 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$15.96 M
|
$13.50 M
|
$14.04 M
|
$12.61 M
|
$11.31 M
|
$8.00 M
|
$10.62 M
|
$7.22 M
|
$4.86 M
|
$6.48 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$486.55 K
|
$0.00
|
-$128.99 K
|
-$303.48 K
|
| Operating Expenses |
$37.14 M
|
$27.62 M
|
$31.38 M
|
$27.69 M
|
$20.52 M
|
$14.61 M
|
$17.27 M
|
$11.43 M
|
$7.06 M
|
$6.95 M
|
| Cost And Expenses |
$37.14 M
|
$27.62 M
|
$31.38 M
|
$27.69 M
|
$20.52 M
|
$14.61 M
|
$17.27 M
|
$11.43 M
|
$7.19 M
|
$7.25 M
|
| Interest Income |
$2.38 M
|
$4.05 M
|
$4.34 M
|
$877.00 K
|
$6.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$192.82 K
|
$0.00
|
| Depreciation & Amortization |
$16.00 K
|
$17.00 K
|
$23.00 K
|
$8.00 K
|
$23.00 K
|
$47.00 K
|
$52.79 K
|
$44.20 K
|
$128.99 K
|
$303.48 K
|
| EBITDA |
-$37.13 M |
-$27.60 M |
-$31.35 M |
-$27.68 M |
-$20.50 M |
-$14.56 M |
-$17.21 M |
-$11.39 M |
-$7.80 M |
-$6.07 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$2.37 M
|
$2.12 M
|
$1.28 M
|
$731.00 K
|
-$85.00 K
|
-$3.22 M
|
$25.65 K
|
$29.30 K
|
-$935.13 K
|
$880.74 K
|
| Income Before Tax |
-$34.77 M
|
-$25.50 M
|
-$30.09 M
|
-$26.96 M
|
-$20.61 M
|
-$17.83 M
|
-$17.24 M
|
-$11.40 M
|
-$8.12 M
|
-$6.37 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$29.30 K
|
$0.00
|
$0.00
|
| Net Income |
-$34.77 M
|
-$25.50 M
|
-$30.09 M
|
-$26.96 M
|
-$20.61 M
|
-$17.83 M
|
-$17.24 M
|
-$11.40 M
|
-$8.12 M
|
-$6.37 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-4.04 |
-3 |
-3.6 |
-3.15 |
-2.7 |
-29.55 |
-30.45 |
-82.5 |
-164.55 |
-388.95 |
| EPS Diluted |
-4.04 |
-3 |
-3.6 |
-3.15 |
-2.7 |
-29.55 |
-30.45 |
-82.5 |
-164.55 |
-388.95 |
| Weighted Average Shares Out |
$8.61 M
|
$8.39 M
|
$8.41 M
|
$8.44 M
|
$7.80 M
|
$753.90 K
|
$566.46 K
|
$277.18 K
|
$64.99 K
|
$16.37 K
|
| Weighted Average Shares Out Diluted |
$8.61 M
|
$8.39 M
|
$8.41 M
|
$8.44 M
|
$7.80 M
|
$753.90 K
|
$566.46 K
|
$277.18 K
|
$64.99 K
|
$16.37 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
